SNTI Stock Analysis
SN
Uncovered
Senti Biosciences Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Senti Biosciences, Inc. operates as a biotechnology company. The company is headquartered in South San Francisco, California. The company went IPO on 2021-05-26. The firm is developing cell and gene therapies engineered with its gene circuit platform technologies to cure diseases. Its advanced gene-circuit product candidates are directed at allogeneic CAR-NK cells for oncology. Its preclinical stage product candidates include SENTI-202, SENTI-301 and SENTI-401. The company is developing its SENTI-202 product candidate as a Logic Gated (OR + NOT) allogeneic CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML), cells while sparing the healthy bone marrow. Its SENTI-301 product candidate is a multi-Armed allogeneic CAR-NK cell therapy that it is developing for the treatment of hepatocellular carcinoma (HCC). Its SENTI-401 product candidate is a Logic-Gated allogeneic CAR-NK cell therapy that it is developing to target and eliminate colorectal cancer (CRC) cells. Gene circuit platform is its technology platform.